Your gift is 100% tax deductible
Tumor Treating Fields (TTFields) for Brain Tumors in Adults
Tumor treating fields (TTFields) are low-energy alternating electrical fields that disrupt the ability of certain tumor cells to grow and divide. Optune Gio is a wearable TTFields device approved to treat some people with glioblastoma.
When might TTFields be used for brain tumors?
Optune Gio can be used:
- Along with chemotherapy in people with glioblastoma after treatment with surgery and radiation therapy. It may help people live longer than if they just get chemotherapy alone.
- Instead of chemotherapy if glioblastoma has come back after initial treatment. It hasn’t been shown to help people live longer than chemotherapy in this situation, but it tends to have much milder side effects.
What to expect during TTFields treatment
For this treatment, your head is shaved, and 4 sets of adhesive pads with electrodes are placed on your scalp. The pads are attached to a battery pack (kept in a backpack) and are worn for most of the day. The electrodes create mild electric currents that are thought to affect tumor cells in the brain more than normal cells.
Possible side effects of TTFields
Side effects of the device used for TTFields tend to be minor and can include skin irritation at the electrode sites, trouble sleeping, mood changes, and a slightly increased risk of headaches and seizures.
Learn more: Tumor Treating Fields (TTFields)/Electrical Fields
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Batchelor T. Initial treatment and prognosis of IDH-wildtype glioblastoma in adults. UpToDate. 2025. Accessed at https://www.uptodate.com/contents/initial-treatment-and-prognosis-of-idh-wildtype-glioblastoma-in-adults on September 16, 2025.
Batchelor T, Shih HA, Carter BS. Management of recurrent high-grade gliomas in adults. UpToDate. 2025. Accessed at https://www.uptodate.com/contents/management-of-recurrent-high-grade-gliomas-in-adults on September 16, 2025.
Dorsey JF, Salinas RD, Dang M, et al. Chapter 63: Cancer of the central nervous system. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Central Nervous System Cancers. Version 2.2025. Accessed at www.nccn.org on September 16, 2025.
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306-2316.
Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-202.
Last Revised: January 5, 2026
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


